Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Rule Clarifying Parameters For Discount Drug Program Is Planned By Year-End, HRSA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Both pharmaceutical manufacturers and 340B hospitals seek more specifics on issues such as which patients are eligible to receive deeply discounted drugs through the program, how to contract with outside pharmacies and obligations of manufacturers and eligible hospitals.


Related Content

Senior Senators Seek Details On Government Audits Of 340B Entities
340B Drug Audits: HRSA Reviewing 51 Entities In 2012


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts